in Spain, its current prevalence ranges between 2833%11,12 and it is a recognized as a cardiovascular risk factor and increases the mortality in this population.1315 Furthermore, in patients with DM2 and advanced CKD there are limitations in the prescription of certain antihyperglycemic drugs (e.g., metformin or sulfonylureas) and there is an increased risk of hypoglycemia with antihyperglycemic treatment,16 a complication that is associated with increased cardiovascular risk17 and hinders the achievement of glycemic control targets
With telehealth providers like Hers, Nurx, Ro, and Alloy, you can book a virtual consultation with a medical provider to learn more about your candidacy and whether or not these weight loss medications are the right option for you
Patients in Stamford, Greenwich, Fairfield County, and throughout Connecticut can call 203-348-8805 to discuss physician-supervised GLP-1 weight loss options
Reid CT, Tobin AM, Ahern T, OShea D, Kirby B
Please share your story through Legislative Action Center at the link below